Who are Divalproex (DV)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Duvyzat, Farydak, Beleodaq, BELINOSTAT, Istodax, Zolinza.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/divalproex-dv.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Divalproex (DV) — Competitive Intelligence Brief

Divalproex (DV) (Divalproex (DV)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histone deacetylase inhibitor; anticonvulsant; mood stabilizer. Area: Neurology; Psychiatry.

marketed Histone deacetylase inhibitor; anticonvulsant; mood stabilizer Histone deacetylase; GABA metabolism; sodium and calcium channels Neurology; Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Divalproex (DV) (Divalproex (DV)) — Weill Medical College of Cornell University. Divalproex inhibits histone deacetylase and enhances GABA neurotransmission, leading to increased inhibitory signaling in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Divalproex (DV) TARGET	Divalproex (DV)	Weill Medical College of Cornell University	marketed	Histone deacetylase inhibitor; anticonvulsant; mood stabilizer	Histone deacetylase; GABA metabolism; sodium and calcium channels
Duvyzat	GIVINOSTAT	Italfarmaco Spa	marketed	Histone Deacetylase Inhibitor [EPC]		2024-01-01
Farydak	PANOBINOSTAT	Secura	marketed	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
Beleodaq	belinostat	Acrotech Biopharma	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 1	2014-01-01
BELINOSTAT	BELINOSTAT		marketed	Histone Deacetylase Inhibitor [EPC]		2014-01-01
Istodax	ROMIDEPSIN	Teva Pharms Usa Inc	marketed	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Zolinza	VORINOSTAT	Merck & Co.	marketed	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histone deacetylase inhibitor; anticonvulsant; mood stabilizer class)

National Institute on Drug Abuse (NIDA) · 1 drug in this class
Sanofi · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Divalproex (DV) — Competitive Intelligence Brief. https://druglandscape.com/ci/divalproex-dv. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab